Clinical Trials in Baltimore

Showing 3681-3700 of 20,142 trials

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

NCT06014255

This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.

Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins219 participantsStarted Feb 2024

Chicago, Illinois, United States • Baltimore, Maryland, United States • Minneapolis, Minnesota, United States +2 more locations

COMPLETEDNA< 1 mile

Muscle Capillarization and Sarcopenia

NCT03984994

Aging is associated with a loss of muscle mass, termed sarcopenia, that reduces mobility, decreases physical function and accelerates progression of other age-related disorders. This study is designed to determine whether increasing skeletal muscle capillarization through aerobic exercise will enhance muscular adaptations to strength training in older adults with sarcopenia.

Sarcopenia

Baltimore VA Medical Center14 participantsStarted Nov 2021

Baltimore, Maryland, United States • College Park, Maryland, United States

Active Not RecruitingPhase 1/2< 1 mile

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT03172754

This is a Phase I/II, open-label, multi-center study of axitinib in combination with nivolumab in patients with previously treated and untreated advanced RCC. This clinical study will be composed of a dose finding phase (Phase I) and two parallel dose expansion phases (Phase II). The dose finding phase will assess the safety of the combination and establish a recommended phase II dose (RP2D, the highest tested dose that is declared safe and tolerable by the Investigators and the Sponsor Investigator) in patients with advanced RCC who have received prior systemic therapy for metastatic disease. Phase II will evaluate the efficacy of the combination at the RP2D in two parallel expansion cohorts in both previously treated and treatment naïve patients.

Renal Cell Carcinoma

Fox Chase Cancer Center98 participantsStarted Jun 2017

Baltimore, Maryland, United States • Albany, New York, United States • New York, New York, United States +1 more locations

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Muscle Capillarization and Sarcopenia

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Find Trials by Condition in Baltimore

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Behavioral Assessment and Treatment of Problem Behavior in Children With Cornelia de Lange Syndrome

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Evaluation of Patients With Gastrointestinal Disease

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Using Re-inforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

STXBP1 and SYNGAP1 Related Disorders Natural History Study

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia

Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Access Cannulation Trial II

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)